FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation) (Commission File Number) Delaware 001-40739 86-3218736 (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) (858) 800 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ___________ Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in the charter) | Delaware | 86-3218736 | | - ...

- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne -- Over 30 million acne patients seek treatment in the U.S. each year -SAN DIEGO, March 26, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology compan ...

EX-99.1 2 drma_ex991.htm PRESS RELEASE EXHIBIT 99.1 Anticipated Upcoming Milestones - Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 – - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) Delaware 86-3218736 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 3525 Del Mar Heights Rd., #322, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 San Diego, CA 92130 Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) (State ...

- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America - SAN DIEGO, March 4, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last ...

EX-99.1 2 drma_ex991.htm PRESS RELEASE EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 – SAN DIEGO, CA, November 13, 2024 – Dermata Therapeutics, Inc. (Nasdaq: DRM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ___________ Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in the charter) | --- | |---------------- ...

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetics skin diseases and conditions, today announced that Gerry Proehl, Chairman, President, and Chief Executive Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, on Thursday, November 14, 2024 at 12:00 PM ET. Date: November 14, 2024 Time: 12:00pm – 12:3 ...

EX-99.1 2 drma_ex991.htm PRESS RELEASE EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - - Dermata continues discussions with potential botulinum toxin partners for DMT410 – - Raised $2.3 million in net proceeds from financing completed in 2Q 2024 - SAN DIEGO, CA, August 7, 2024 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) ("Derma ...